Aethlon receives clearance from drug controller general of india for potential phase 1 trial of its hemopurifier® in oncology

San diego , oct. 10, 2023 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it has received clearance from the drug controller general of india (dcgi), the central drug authority in india, to conduct a phase 1 safety, feasibility and dose-finding trial of the company's hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-pd-1 monotherapy treatment, such as keytruda® or opdivo®. the trial is expected to begin following completion of an internal in vitro binding study of relevant targets, and subsequent approval by the respective ethics boards of interested sites in india.
AEMD Ratings Summary
AEMD Quant Ranking